J&J leans on Tremfya, cancer drugs to overcome Stelara losses
BioPharma Dive
A growing multiple myeloma franchise helped the pharmaceutical giant top Wall Street s expectations and surpass $15 billion in first-quarter drug sales.
pharminent
April 14, 2026 (Last updated: April 14, 2026)
BioPharma Dive
A growing multiple myeloma franchise helped the pharmaceutical giant top Wall Street s expectations and surpass $15 billion in first-quarter drug sales.
